



PROGRAM OUTLINE

Tuesday 2 June 2026

17:30 – 19:30	EMCR Sundowner
	<i>A casual event for students, early and mid-career researchers to get together prior to the start of the congress the following day at a venue to be announced. Drinks at guests own expense with light nibbles supported by Dr Sue Fletcher.</i>


Wednesday 3 June 2026

09:00 – 09:30	OFFICIAL OPENING
	Welcome to Country
	ANN Welcome Dr Ian Woodcock, President, Australasian Neuromuscular Network
	AOMC Welcome Dr Ichizo Nishino, President, The Asian and Oceanian Myology Center
	NMWA Welcome Cara Philpott, Chair, Neuromuscular WA
	Patient Experience Sarah & Colin Ye
09:30 – 10:30	PLENARY SESSION 1
	KEYNOTE ADDRESS: Metabolic Myopathies & Rhabdomyolysis Prof Ros Quinlivan Queen Square Centre for Neuromuscular Disease, United Kingdom
10:30 – 11:00	Morning Tea
11:00 – 12:30	Themed Symposium 1: Metabolic Myopathies & Rhabdomyolysis
11:00	Exploring genetic predisposition to rhabdomyolysis Dr Emily Oates Sydney Children's Hospital Network and The University of New South Wales, Australia

11:30	The update of lipid storage myopathy Dr Wen-Chen Liang Kaohsiung Medical University Hospital, Taiwan
12:00	Metabolic/lipid storage myopathy - insights from Asia Dr Duolong Li Qilu Hospital of Shandong University, China
12:30 – 13:15	Lunch
13:15 – 15:15	Lightning Talks EMCR Presentations
	How, when, and why should we talk to young people with nmd about dying? Dr Kathryn Irving Royal Children's Hospital Melbourne, VIC, Australia
	Missense variants in TUBA4A cause myo-tubulinopathies Dr Mridul Johari Harry Perkins Institute of Medical Research, WA, Australia
	Lactate and histone lactylation mediate a multi-organ crosstalk by upregulating myokine GDF15 in mitochondrial myopathy Prof Yan Lin Qilu Hospital of Shandong University, Shandong, China
	Mitochondrial dysfunction driven by imbalanced fission and fusion of mitochondria in myofibrillar myopathy type 5 Dr Xiaoqing Lyu Qilu Hospital of Shandong University, China
	Reversing Cardiac Dystrophinopathy: Insights from a Human XLDCM iPSC Model and P188 Therapy. Dr Yin Cheng The University of Hong Kong, Hong Kong
	Optical genome mapping in australian clinical diagnostics: a retrospective analysis of FSHD1 testing at Pathwest Dr Harmony Clayton PathWest Laboratory Medicine, Australia
	Mental and Intellectual Neuro Development in childhood-onset FSHD Studies – the MINDS FSHD Protocol Dr Katy de Valle Murdoch Children's Research Institute, Australia
	Exon-skipping therapies for dmd boys in Kazakhstan: Challenges of implementation A/Prof Altyنشash Jaxybayeva Center for Molecular Medicine, Kazakhstan
	Concurrent and cross-contextual validity of the functional mobility scale for children with neuromuscular disease Dr Rachel Kennedy Murdoch Children's Research Institute, Australia
	Clinical, Radiological and Genetic Spectrum of ADSSL1 Myopathy: A Case Series Dr Farsana Mustafa All India Institute of Medical Sciences, India
	Integrative multi-omics identifies MRPL30 as novel mitochondrial disease gene Miss Andi G. Penklis University of New South Wales, Australia
	Efgartigimod Non-Responders in Generalized Myasthenia Gravis: A Retrospective Analysis of Predictive Factors Miss Jingru Ren Peking University First Hospital, China

	<p>Precision therapeutic development for ADSS1 myopathy integrating AI-guided discovery with a novel knock-in model Dr Cara Timpani Victoria University, Australia</p> <p>Muscle imaging patterns and variant-specific progression in DNM2-related centronuclear myopathy Dr Genevieve Gucci Grace Uj NCNP, Japan</p> <p>The mislocalization of TDP-43 to mitochondria impairs myotube maturation Dr Yalan Wan Peking University First Hospital, China</p>
15:15 – 15:40	Afternoon Tea
15:40 – 17:00	Poster Session 1
17:00 – 18:00	<p>Debate: AI Replacing Clinicians & Researchers</p> <p>Participants: Dr Michelle Lorentzos The Sydney Children's Hospitals Network, Australia</p> <p>Dr Ian Woodcock, Royal Children's Hospital, Australia</p> <p>Dr Crystal Jing Jing Yeo National Neuroscience Institute, Singapore</p>
18:00 – 19:30	Welcome Reception

Thursday 4 June 2026

08:00 – 09:00	<p>Breakfast Symposia Dr Vivek Mundada (United Arab Emirates)</p>	<p>Presented by</p> 
09:00 – 10:30	Themed Symposium 2: Inflammatory Myopathies	
09:00	<p>IBM Prof Merrilee Needham Fiona Stanley Hospital, Australia</p>	
09:30	<p>Immune Checkpoint Inhibitor Myopathy: A Journey from Bedside to Bench and Back to Bedside Prof Teerin Liewluck Mayo Clinic-Rochester, United States</p>	
	<p>Real-world study of eculizumab for the treatment of Chinese patients with inclusion body myositis Dr Qiang Gang Peking University First Hospital, China</p> <p>ZNF683-Positive tissue-resident memory T cells anchor the inflammatory-myofiber-interstitial axis in inclusion body myositis Dr Francia Victoria De Los Reyes National Institute of Neuroscience, National Center of Neurology and Psychiatry, Japan</p> <p>Clinical, imaging, and muscle pathological characteristics of different subtypes of juvenile idiopathic inflammatory myopathies</p>	

	A/Prof Cuijie Wei Peking University First Hospital, China
	Patient Story
10:30 – 11:00	Morning Tea
11:00 – 12:30	Short Oral Presentations Session 2
	Therapeutic possibilities for PYROXD1 myopathy Dr Frances Evesson The University of Sydney, Australia
	Defects in lysosome reformation - A novel link between genetically distinct muscular dystrophies and myopathies Dr Meagan Mcgrath Monash University, Australia
	Summarising lower limb contractures affecting gait and function in ambulant boys with Duchenne Muscular Dystrophy Dr Kate Carroll The Royal Children's Hospital, Australia
	A new beginning for Duchenne: Genomic newborn screening and integrated models of early care Dr Michelle Lorentzos The Sydney Children's Hospitals Network, Australia
	Late-onset TK2 deficiency in adults: Long-term clinical outcomes of deoxynucleoside therapy Dr Hacer Durmus Tekce İstanbul Üniversitesi Çapa Tıp Fakültesi, Turkey
	Diagnostic yield of high-risk screening for late-onset pompe disease in thailand Prof Oranee Sanmaneechai Faculty of Medicine Siriraj Hospital Mahidol University, Thailand
	Essence: efficacy and safety of golodirsen and casimersen compared with placebo in Duchenne Muscular Dystrophy Dr Gerard Sheehan Sarepta Therapeutics, Ireland
	Natural history and outcome measures in Facioscapulohumeral muscular dystrophy in India A/Prof Venugopalan Vishnu All India Institute of Medical Sciences, India
12:30 – 13:15	Lunch & EMCR Networking
13:15 – 15:15	Themed Symposium 3: Disease Modelling & Emerging Therapies
13:15	Outcome measures in LGMD in era of therapies Dr Meredith James John Walton Muscular Dystrophy Research Centre, United Kingdom
13:55	Modelling myopathies and evaluating therapies using patient-derived cells and engineered muscle tissues Dr Joshua Clayton Harry Perkins Institute of Medical Research, Australia
14:20	AI-driven biomarker discovery and stem cell modelling in Motor Neuron Disease Dr Crystal Jing Jing Yeo National Neuroscience Institute, Singapore
14:45	Genetic Discovery and Modelling Inherited Neuropathies Prof Marina Kennerson

	Northcott Neuroscience Laboratory, ANZAC Research Institute Sydney Local Health District & University of Sydney, Australia
15:15 – 15:40	Afternoon Tea
15:40 – 17:00	Poster Session 2 & Clive Film Here
18:30 – Late	Conference Dinner Venue: <i>Frasers Kings Park</i> Guests to make their own way to venue

Friday 5 June 2026	
09:00 – 10:30	AOMC Plenary Session
09:00	KEYNOTE ADDRESS: Rare Care experience, an NMD focus Prof Jong-Hee Chae Seoul National University College of Medicine, South Korea)
09:40 – 10:30	Transition Care
09:40	Transition for DMD Professor Ros Quinlivan Queen Square Centre for Neuromuscular Disease, United Kingdom
10:00	Patient Perspective Bailey and Mike Atkinson
10:30 – 11:00	Morning Tea
11:00 – 12:30	Themed Symposium 4: Foundations & Frontiers in Neuromuscular Care
11:00	Respiratory health Dr Adelaide Withers Perth Children's Hospital, Australia
11:30	Redefining physiotherapy in the age of disease modifying therapies Dr Kristy Rose Sydney Children's Hospitals Network (Randwick and Westmead), Australia
12:00	Clinical trials and readiness, NZ perspective A/Prof Richard Roxburgh New Zealand
12:30 – 13:15	Lunch & ANN AGM
13:15 – 15:00	Concurrent Sessions
	Interesting Cases
	Community-focused session: Therapies and equity of access
	Equity and access around the globe Dr Michelle Lorentzos The Sydney Children's Hospitals Network, Australia
	Exon skipping for NMDs Prof Emerita Sue Fletcher Murdoch University, Australia
	Novel CFL2 missense variants impair F-ACTIN depolymerisation and expand cfl2-related myopathy spectrum Ms Lein Dofash Harry Perkins Institute of Medical Research, Australia
	Clinical and Genetic Analysis of LGMD R1 Caused by Novel Non-canonical CAPN3 Splicing Mutations Dr Meirong Liu

	The First Affiliated Hospital of Soochow University, China	
	LDB3 Mutation–Associated Myofibrillar Myopathy in a Filipino Mother and Daughter: A First Report Dr Mark Jenzen Trivilegio University of Santo Tomas Hospital, Philippines	
	BI-ALLELIC variants in DMXL1 Cause a Novel Autophagic Vacuolar Myopathy Ms Chiara Folland Harry Perkins Institute of Medical Research, Australia	The Perth Rare Care Centre Therapies Flagship Dr May Aung-Htut Murdoch University, Australia
	A severe neurodevelopmental syndrome caused by a founder CDK5RAP3 variant in The Indian/Nepalese Population Dr Michaela Yuen Children's Medical Research Institute, Australia	
15:00 – 15:30	Afternoon Tea	
15:30 – 16:00	Closing Session	
	Awards & Closing Ceremony Gina Ravenscroft, Ichizo Nishino, Ian Woodcock	